Clinical Trials Now Enrolling Volunteers
Trials near you
About volunteering for clinical trials
About type 1 diabetes
About the Immune Tolerance Network
HOME ITN and Study Contacts

 

California

Los Angeles
The Rituximab Study

San Francisco
The AbATE Trial - hOKT3γ1(Ala-Ala) in newly diagnosed type 1 diabetes patients
The Rituximab Study

Stanford
The Rituximab Study

Colorado

Denver
The AbATE Trial - hOKT3γ1(Ala-Ala) in newly diagnosed type 1 diabetes patients
The Rituximab Study

Florida

Gainesville
The Rituximab Study

Miami
The Rituximab Study

Indiana

Indianapolis
The Rituximab Study

Minnesota

Minneapolis
The Rituximab Study

New York

New York City
The AbATE Trial - hOKT3γ1(Ala-Ala) in newly diagnosed type 1 diabetes patients
The Rituximab Study

Pennsylvania

Pittsburgh
The Rituximab Study

Texas

Dallas
The Rituximab Study

Washington

Seattle
The AbATE Trial - hOKT3γ1(Ala-Ala) in newly diagnosed type 1 diabetes patients
The Rituximab Study

CANADA

Toronto
The Rituximab Study

 
© 2005 Immune Tolerance Network. All rights reserved.
 
 
Washington Oregon California Idaho Nevada Arizona Utah New Mexico Colorado Wyoming Montana North Dakota South Dakota Nebraska Kansas Oklahoma Texas Louisiana Arkansas Missouri Iowa Minnesota Mississippi Tennessee Kentucky Illinois Wisconsin Michigan Michigan Indiana Alabama Ohio Florida Georgia South Carolina North Carolina Virginia West Virginia Maryland Maryland Delaware Delaware Pensylvania New Jersey New Jersey New York New York Virginia Michigan South Carolina North Carolina Alaska Alaska Alaska Alaska Alaska Hawaii Hawaii Hawaii Hawaii Hawaii Hawaii Hawaii Connecticut Connecticut Rhode Island Rhode Island Massachusetts Massachusetts Vermont Vermont New Hampshire New Hampshire Maine